Weidinger, Franz

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

Empagliflozin in acute myocardial infarction: the EMMY trial

von Lewinski, D., Kolesnik, E., Tripolt, N. J., Pferschy, P. N., Benedikt, M., Wallner, M., Alber, H., Berger, R., Lichtenauer, M., Saely, C. H., et al. (2022) · European Heart Journal

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 303

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 118

Wearables, telemedicine, and artificial intelligence in arrhythmias and heart failure: proceedings of the European Society of Cardiology cardiovascular round table

Leclercq, C., Witt, H., Hindricks, G., Katra, R. P., Albert, D., Belliger, A., Cowie, M. R., Deneke, T., Friedman, P., Haschemi, M., et al. (2022) · EP Europace

ECG Monitoring and AnalysisMobile Health and mHealth Applications

Cited by 109